Medimmune is perhaps the region's premier biopharma company. "Medi" has thrived since its acquisition by AstraZeneca. Believing that a stronger regional cluster makes a stronger company, AZ/Medimmune has set a strategic goal of developing the region into national preeminence. Medimmune hosted a "top 3 by 2023" at their headquarters last Spring and will do the same this year. It is organizing and funding a regional branding process involving a wide network of Virginia, DC, and Maryland stakeholders, organizing a series of CEO dinners, initiating discussions with state officials to partner with the Commonwealth to grow the biotech industry here by developing a network of spin-off companies across the state by contributing developmental drug assets, cash, and in-kind contributions.
Leaders from Medimmune responsible for creating and implementing this regional development strategy will discuss their vision and their efforts, with emphasis on the potential impact on and involvement of the bioscience industry across Virginia.
- Reg Seeto, Vice President, Head of Partnering and Strategy
- Jarrod Borkat, Head of External Collaborations, Biotech Hubs and Government
For more information, click here.